News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)Why we need to avoid recurrent events: Plaque biology considerations REDUCE-IT- does the formulation matter?REDUCE-IT take home messages ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

AHA Scientific Sessions 2018

ODYSSEY OUTCOMES Economic Study

Novel lipoprotein(a) antisense therapy looks good

ODYSSEY OUTCOMES total events analysis

New US Cholesterol Guidelines

News from ESC Congress 2018

News from ISA 2018

Most viewed

Do PCSK9 inhibitors increase new-onset diabetes? Another meta-analysis PCSK9 inhibitors: effects on glycaemia and HbA1c VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study ODYSSEY DM-Dyslipidemia ODYSSEY DM – Insulin Alirocumab effects on lipoprotein particles ODYSSEY Outcomes ESC 2018: FOURIER analysis: Greater benefit with evolocumab in metabolic syndrome patients VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) VIDEO: New insights from ODYSSEY OUTCOMES

Most viewed

Do PCSK9 inhibitors increase new-onset diabetes? Another meta-analysis

A new genetic mechanism for familial hypercholesterolaemia: PCSK9 whole gene duplication

Familial hypercholesterolemia (FH) patients continue to teach us new things about lipid metabolism. Prof Robert A. Hegele, Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada discusses new insights into FH genetics.

Read the report

Hot Topics

Guidance needed on LDL lowering in very high-risk patients

Do high and very high-risk patients at guideline-recommended goal gain more benefit from further lowering LDL cholesterol levels?

PCSK9 Forum Editor Professor John Chapman (UPMC-Sorbonne, Director Emeritus, INSERM, Paris, France), discusses.

Read the report

Video: Impetus to change LDL-C goal from FOURIER
Watch the video

From the Editors

Is LDL-apheresis still needed in the PCSK9 era?

With the advent of PCSK9 monoclonal antibodies, reduction in LDL-cholesterol levels by up to 80-90% is now possible, when combined with statins and ezetimibe. What role does LDL-apheresis have in this new era?